-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Epilepsy Clinical Trial Report Overview A total of 3474 epilepsy clinical trials were conducted as of April 2024. The epilepsy clinical trial report provides a comprehensive understanding of the epilepsy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe ·      Asia-Pacific ·      ...
-
Product Insights
Globoid Cell Leukodystrophy (Krabbe Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Globoid Cell Leukodystrophy (Krabbe Disease) - Drugs In Development, 2023’, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BIA-286156 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BIA-286156 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIA-286156 in Parkinson's Disease Drug Details: BIA-286156 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CK-0804 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CK-0804 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)Drug Details:CK-0804 is under development for the treatment of primary...
-
Product Insights
Parkinson’s Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Parkinson’s Disease Clinical Trials Market Report Overview In total there were 2,622 clinical trials conducted on Parkinson's Disease, as of February 2023, of which the majority of clinical trials were in Europe. The Parkinson’s Disease clinical trial market research report provides an overview of the clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Product Insights
Globoid Cell Leukodystrophy (Krabbe Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability, and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care. The Globoid Cell Leukodystrophy (Krabbe Disease) pipeline market research report provides comprehensive information on the therapeutics under development...
-
Product Insights
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue, and seizures. Treatment includes enzyme replacement therapy. The Gaucher Disease pipeline market research report provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....